Total amount: € 0,00
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,236
Online ISSN 1827-1669
Bosco D. 1, Plastino M. 1, Bosco F. 2, Fava A. 3, Rotondo A. 4
1 Operative Unit of Neurology, “S. Giovanni di Dio”, Crotone, Italy;
2 Pharmacology, Course of Clinical Pharmacy, loc. Roccelletta “Magna Graecia” University, Catanzaro, Italy;
3 Department of Endocrinology and Metabolism, “Magna Graecia” University, Catanzaro, Italy;
4 Department of Psychiatry, Neurobiology, Pharmacology, and Biotechnology, University of Pisa, Pisa, Italy
AIM: Aim of the present study was to evaluate the clinical efficacy, tolerability and quality-of-life measures to melevodopa in advanced Parkinson’s disease (PD) with motor fluctuations (MFs).
METHODS: A total of 37 patients with advanced PD and MFs participated in the study. Patients were switched from standard l-dopa/carbidopa to melevodopa and were treated for 10 weeks.
RESULTS: Assessment of “On-Day” time demonstrated improvement to about 0.7 hour in the melevodopa treatment. The benefit was greater in patients with “delayed-on” (P=0.002) and especially in those with both “delayed-on” and “wearing-off” (P<0.001). Most patients showed a significant improvement in PDQ-39 total score (P=0.002) and PSI distress domain (P<0.001). Instead, not significant difference was observed in patients with only wearing-off.
CONCLUSION: These data show that melevodopa is an effective agent for improving daily motor performance and quality-of-life in PD with “delayed-on”, also in association with “wearing-off”.